ScinoPharm invests $37M in high potency cytotoxic injectable plant

Friday, June 29, 2012 02:50 PM

ScinoPharm, a Taiwanese provider of oncological APIs for injectable products, has decided to invest $37.6 million in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company's premise at the Tainan Science Park.

"By expanding into the field of oncological injectable formulation, ScinoPharm will be able to provide a vertically integrated, one-stop-shop service for our existing API customers," said Dr. Jo Shen, president and CEO of ScinoPharm. "The global demand for oncological injectable production capacity far exceeds the supply. Many international generic customers of ours have been eagerly searching for partners who can provide a high quality and stable supply of oncological injectable drug products not to mention meet GMP requirements. We are excited to be able to fill this critical requirement.”

The entire facility will include space for R&D, quality control, washing, sterilization, manufacturing, filling, lyophilization, packaging and storage. There will be one line for the oncological production, capable for producing liquid vials as well as lyophilized vials.  In a separate, isolated area, there will also be equipment for prefilled syringes dedicated for non-cytotoxic products. This special capability was added again as a response to the severe shortage of capacity in the market.

The entire injectable plant will meet the international cGMP standards of the sterile facility. For the cytotoxic area, where high potency oncological products will be produced, sophisticated containment equipment will be installed with proper safety protection.

Design and construction of the plant is expected to begin in the second half of 2012, with completion expected in 2014. ScinoPharm's main objective is to provide value-added services to the existing customers through contract manufacturing services of oncological injectable form. Through the expanded capabilities, ScinoPharm hopes to further solidify its leadership position in the oncological area with enhance support to its customers.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs